Jouhou Koukai News

Research findings cited by Nihon Keizai Shimbun es

Thur, 11 Mar 2010 20:15:48 +0900

show that in spite of sales deregulations for OTC drugs the actual sales in 2009 have decreased by 0.4% due to the significant number of people visiting clinics instead of purchasing cold medicines by themselves

The MHLW in conjunction with the Drug Price Subcommittee

Mon, 08 Mar 2010 18:05:23 +0900

of the Central Social Insurance Medical Council (CSIMC) announced the plan for 10 years post-approval price protection for all patented drugs; orphan and other niche products are projected to benefit most

Tokyo Stock Exchange (TSE) announced the 2009 Listed Company Awards:

Sun, 07 Mar 2010 17:05:43 +0900

Kyowa Hakko Kirin KK granted the 15th Corporate Disclosure Award

Pharmaceuticals and Medical Devices Agency (PMDA) released

Thur, 04 Mar 2010 18:21:23 +0900

the updated Japan Drug Master Files listing of over 7,000 entries

Lunkbeck Japan to initiate two Phase III studies with new anti-depressants

Wed, 03 Mar 2010 11:15:43 +0900

Danish pharma company H Lundbeck A/S (CPH: LUN) and its R&D partner Japanese Takeda Pharmaceutical Company Ltd (TYO: 4502) said today they will start pivotal clinical phase III studies with two depression drugs. The candidate drugs Lu AA21004 andLu AA24530 will be studied in patients with major depressive disorder (MDD).

The programme on Lu AA21004, which is expected to start in the first half of 2010, will comprise four clinical phase III studies including about 2,000 patients in addition to a long-term extension study. The planned doses are 10 mg, 15 mg and 20 mg.

The clinical phase III studies with Lu AA24530 will start with four individual trials, including a long-term study and a relapse prevention study. About 2,000 patients are planned to be included investigating doses at 10 mg and 20 mg. Selected trials will include an active reference compound. The programme is due to begin by the end of 2010 and may also include future phase III studies to further investigate the compound’s benefit and risk profile.

Lu AA21004 is a 5-HT(3), 5-HT(7) and 5-HT(1B) receptor antagonist, 5HT(1A) receptor agonist and 5-HT transporter inhibitor.

In pre-clinical studies, Lu AA24530 has demonstrated activities as a multi-modal enhancer with reuptake inhibition at monoamine transporters, and antagonist activity at 5-HT(3) and 5-HT(2c) receptors.

Date: 3 March 2010 Data sourced from: Nordic Business Report

February 28, 2010: Archived JKS News feeds for 2007-2010

Wed, 31 Dec 2008 23:28:29 +0900

are available here